DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Nivolumab is an investigational drug.
There have been 787 clinical trials for Nivolumab. The most recent clinical trial was a Phase 2 trial, which was initiated on May 15th 2019.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Non-Small-Cell Lung, and Melanoma. The leading clinical trial sponsors are Bristol-Myers Squibb, National Cancer Institute (NCI), and Ono Pharmaceutical Co. Ltd.
There are one hundred US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Nivolumab
|CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)||Huntsman Cancer Institute||Phase 1/Phase 2|
|CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)||OncoImmune, Inc.||Phase 1/Phase 2|
|Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma||Bristol-Myers Squibb||Phase 2|
Top disease conditions for Nivolumab
Top clinical trial sponsors for Nivolumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Nivolumab||Start Trial||Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers||Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)||Start Trial|
|Nivolumab||Start Trial||Antibody-drug conjugates and immunotoxins||Oncomatryx Biopharma, S.L. (Derio, ES)||Start Trial|
|Nivolumab||Start Trial||Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods||Biodesix, Inc. (Boulder, CO)||Start Trial|
|Nivolumab||Start Trial||Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof||KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)||Start Trial|
|Nivolumab||Start Trial||Method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor||Amgen Inc. (Thousand Oaks, CA)||Start Trial|
|Nivolumab||Start Trial||Cancer immunotherapy by disrupting PD-1/PD-L1 signaling||Bristol-Myers Squibb Company (Princeton, NJ)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Nivolumab||European Patent Office||3313818||2035-06-26||Start Trial|
|Nivolumab||World Intellectual Property Organization (WIPO)||2016210262||2035-06-26||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|